Longevity: The Next Drug Category After GLP-1. From Breakthrough Science to Aging Drugs

​Longevity: The Next Drug Category After GLP-1
From Breakthrough Science to Aging Drugs

(part of JPM Week)

📍 Downtown San Francisco (near Union Square)
🗓 Wednesday Evening | January 14, 2026
🕡 Doors: 6:30 PM | Program begins promptly at 7:00 PM | Ends by 10:00 PM
🎟 Investor Briefing & Private Discussion | JPM Week | Curated guest list

About the event

​Aging is becoming a true drug-discovery industry — with profound implications for biotech, pharma, and long-term capital allocation.

​This closed-door investor salon convenes a small, curated group of senior investors and industry leaders for an off-the-record discussion on how this shift is reshaping the structure of biotech and pharmaceutical businesses.

​Nature already provides clear counterexamples to inevitable aging in mammals, such as naked mole rats and certain long-lived bat species. Treating aging as a physical process rather than a biological black box has led to a physics-based framework — often referred to as Gerophysics — which has been recognized by Nature as an emerging scientific discipline.

​As a result, aging is transitioning from an accepted biological fate into a tractable engineering problem, with consequences not only for medicine, but for how future biotech and pharmaceutical businesses are built, financed, and scaled.

​The emergence of GLP-1 drugs demonstrated how reframing a fundamental biological process can give rise to an entirely new, multi-billion-dollar drug category. A growing group of leaders across biotech, pharma, and investment are converging on a similar conclusion — that aging is a druggable biological process capable of anchoring the next major therapeutic category.

​This session examines what makes such category transitions possible, what differentiates durable drug classes from transient trends, and why aging is increasingly positioned to follow a GLP-1–like trajectory — albeit across a broader range of diseases and outcomes.

​What will be discussed

• ​Why aging is moving beyond wellness into a druggable, multi-disease target

• ​Which longevity approaches are unlikely to scale — and which can support real therapeutics

• ​How physics-based models and AI make organism-level aging predictable

• ​What this shift implies for pharma portfolios, investment strategy, and long-term value creation

​A central theme: for the first time, currently living generations may realistically remain healthy long enough to experience a future that was previously out of reach — a structural shift with consequences far beyond healthcare.

​A concrete implementation

​As one example of this broader industry shift, Peter Fedichev, CEO and co-founder of Gero, will deliver a 25-minute lecture outlining a fundamental transition in the field:
from qualitative longevity claims to quantitative models that estimate the real lifespan impact of different approaches — and how such models can be used both to identify the inherent limits of existing strategies and to design new drug programs, in-house and with pharmaceutical partners.

​Gero develops in-house drug programs with the potential to meaningfully impact aging and multiple age-related diseases, has collaborated with major pharmaceutical companies, including Pfizer and Chugai (a member of the Roche Group), and has published its work in Science and Nature Communications.
The company has demonstrated rejuvenation effects in aged mouse models that establish this physics-based framework for aging. Gerophysics is now being applied to the design of separate drug programs, including programs for larger mammals such as dogs, and ultimately for human translation.

​More broadly, Peter Fedichev’s work has helped shape how aging is increasingly approached as a predictable, druggable process across biotech and pharma, influencing both scientific strategy and long-term capital allocation in the field.

​Agenda

​6:30-7:00 Arrival & curated networking
7:00-7:30 Key lecture: Longevity: The Next Drug Category After GLP-1. From Breakthrough Science to Aging Drug
7:30-8:00 Moderated discussion
8:00-10:00 Private salon conversation

​Who this is for

• ​Longevity, biotech, and deep-tech investors

• ​Generalist VCs exploring long-term structural shifts

• ​Strategic funds and family offices

• ​Pharma and life-science executives

​Important note

​This is not a pitch event and there will be no stage fundraising.
Any investment conversations happen privately, selectively, and off-stage.